beta alpha alpha 20r 24r-ethylcholestane
- CAS NO.:4705-29-7
- Empirical Formula: C29H52
- Molecular Weight: 400.72
- MDL number: MFCD00216274
- SAFETY DATA SHEET (SDS)
- Update Date: 2026-09-12 18:55:42
What is beta alpha alpha 20r 24r-ethylcholestane?
The Uses of beta alpha alpha 20r 24r-ethylcholestane
5β-Stigmastane is an analog of β-Sitosterol (S497050); a common sterol found in plants. Also antilipemic and used in the treatment of prostatic adenoma.
Definition
ChEBI: 5beta-stigmastane is a stigmastane.
Properties of beta alpha alpha 20r 24r-ethylcholestane
| Melting point: | 189-190 °C |
| Boiling point: | 464.1±12.0 °C(Predicted) |
| Density | 0.905±0.06 g/cm3(Predicted) |
Safety information for beta alpha alpha 20r 24r-ethylcholestane
Computed Descriptors for beta alpha alpha 20r 24r-ethylcholestane
New Products
2-(2-Chlorophenyl)glycine Propiolic Acid 1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene (±)-amino(2-fluorophenyl)acetic acid trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 1-Pentadecanol 4-(4-Αminophenyl)-3-Morpholinone 3-Morpholino-1-(4-(2-oxopiperidin-1-yl) phenyl)-5,6-dihyropyridin-2-(1H)-one 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one N-cyanoacetylurethane 1H-IndazoleRelated products of tetrahydrofuran
You may like
-
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
471-25-0 Propiolic Acid 98+View Details
471-25-0 -
84145-28-8 98+View Details
84145-28-8 -
trans-3-Benzyloxy-4-methoxy-beta-nitrostyrene 98+View Details
63909-29-5 -
2-(2-Chlorophenyl)glycine 88744-36-9 98+View Details
88744-36-9 -
40216-83-9 trans-4-Hydroxy-L-proline methyl ester hydrochloride 98+View Details
40216-83-9 -
629-76-5 98+View Details
629-76-5 -
1-(3-Hydroxy-4-methoxyphenyl)-2-nitroethene 98+View Details
39816-35-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

